An Economic Red Flag Is Flashing -- and It Points to a Higher 2027 Social Security COLA

Consumer sentiment has hit an all-time low due to inflation concerns, particularly from rising oil prices caused by Iran's disruption of the Strait of Hormuz. This elevated inflation is expected to push the 2027 Social Security COLA higher than the current estimate of 3.9%. However, experts warn that even a higher COLA may not adequately offset rising costs for seniors, especially in healthcare, housing, and utilities, which increase faster than general inflation.

05/31/2026, 5:10 AM • The Motley Fool

Applovin Stock Is Skyrocketing Today: What's Going On?

AppLovin shares surged 12.22% on Wednesday as oil prices fell sharply following hopes of a U.S.-Iran deal that could reopen the Strait of Hormuz. Lower oil prices reduce inflation concerns, giving central banks room to cut rates, which benefits rate-sensitive software companies like AppLovin. However, ongoing geopolitical tensions and Piper Sandler's skepticism about an imminent deal add caution to the outlook.

05/27/2026, 12:46 PM • Benzinga

Why Palo Alto Networks Stock Popped Powerfully on Monday

Palo Alto Networks stock surged 4.35% on Monday as part of a broader tech sector rally. Goldman Sachs published an analysis suggesting legacy tech companies were oversold, while Piper Sandler analyst Rob Owens reiterated an overweight rating and $265 price target after investor meetings, expressing confidence that the company is well-positioned to benefit from AI integration rather than being disrupted by it.

04/13/2026, 7:21 PM • The Motley Fool

Why e.l.f. Beauty Stock Plummeted 34.2% Last Month But Is Gaining in April

e.l.f. Beauty stock fell 34.2% in March due to the Iran war, which disrupted oil shipping and increased petrochemical costs for the cosmetics company, compounded by negative analyst coverage. The stock has recovered 5.3% in April following announcements of a ceasefire and reopening of the Strait of Hormuz.

04/08/2026, 12:18 PM • The Motley Fool

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

OKYO Pharma Limited announced a public offering of 10.8 million ordinary shares at $1.85 per share, expected to raise approximately $20 million in gross proceeds (up to $23 million with underwriter option). The company plans to use proceeds for clinical development of its product candidates, including a Phase 2b/3 trial of its flagship drug urcosimod for neuropathic corneal pain. Piper Sandler & Co. is serving as sole manager, with closing expected on February 17, 2026.

02/12/2026, 10:20 PM • GlobeNewswire

Why Edgewise Therapeutics Stock Crushed the Market on Monday

Edgewise Therapeutics stock surged 4% on Monday after analyst Yasmeen Rahimi from Piper Sandler reiterated an overweight recommendation with a $51 price target. Rahimi flagged the biotech as one of Piper Sandler's best stock ideas for 2026, citing strong potential for its lead cardiovascular drug candidate EDG-7500 for treating hypertrophic cardiomyopathy, with Phase 2 results expected in Q2 2026. The company also has other promising pipeline programs including Sevasemten for muscular dystrophy.

02/09/2026, 8:05 PM • The Motley Fool

Why Braze Stock Is Sinking Today

Braze stock declined after Stifel analyst Parker Lane cut the price target from $45 to $40, marking the second consecutive Monday of analyst downgrades. Despite the negative sentiment, the analyst maintains a buy rating, citing the company's overlooked competitive moat. Braze reported solid Q3 2025 results with 25% year-over-year revenue growth and positive free cash flow of $17.8 million, trading at a discount to its historical valuation.

02/09/2026, 12:25 PM • The Motley Fool

Why Investors Are Pumping the Brakes on Rivian Stock This Week

Rivian stock declined 11.2% this week following two analyst downgrades. Wolfe Research downgraded the stock to underperform with a $16 price target, citing continued EBITDA losses and concerns about reduced EV demand. UBS also downgraded to sell with a $15 price target. However, not all analysts are bearish—Piper Sandler raised its price target to $20, showing mixed sentiment on the stock's direction.

01/15/2026, 5:05 PM • The Motley Fool

Tesla’s Earnings Loom With Almost No Room for Error

Tesla faces its upcoming earnings report with significant tension as the stock navigates conflicting analyst outlooks. While bears cite declining production, intensifying competition, and an extremely high P/E ratio of 300 as warning signs, bulls argue the market underestimates Tesla's diversification into robotics, energy, and autonomous driving. The stock's technical strength heading into earnings means results must be near-perfect to justify current valuations.

01/15/2026, 2:32 PM • Investing

Tesla’s Earnings Loom With Almost No Room for Error

Tesla faces its upcoming earnings report with significant tension as the stock navigates conflicting analyst outlooks. While bears cite declining production, intensifying competition, and an extremely high P/E ratio of 300 as warning signs, bulls argue the market underestimates Tesla's diversification into robotics, energy, and autonomous driving. The stock's current uptrend means strong results could validate the bullish case, but any disappointment could trigger a severe repricing given the lofty valuation.

01/15/2026, 1:27 PM • Investing

Protara Announces Pricing of $75 Million Public Offering

Protara Therapeutics plans to raise approximately $75 million through a public offering of 13,043,479 common stock shares at $5.75 per share, with proceeds intended to fund clinical development of TARA-002 and other programs.

12/04/2025, 10:03 PM • GlobeNewswire

Protara Announces Proposed Public Offering

Protara Therapeutics plans to raise $75 million through a public offering of common stock and pre-funded warrants. The proceeds will fund clinical development of TARA-002 and other clinical programs, with J.P. Morgan, TD Cowen, and Piper Sandler acting as joint book-running managers.

12/04/2025, 4:15 PM • Benzinga

Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares

Kestra Medical Technologies is conducting a public offering of 6,000,000 common shares at $23.00 per share, expecting to raise $138 million. The offering includes an option for underwriters to purchase an additional 900,000 shares.

12/02/2025, 10:11 PM • GlobeNewswire

Amneal to Participate in Upcoming Investor Conferences

Amneal Pharmaceuticals executives Chirag Patel and Tasos Konidaris will participate in two upcoming healthcare investor conferences in December 2025 and January 2026, presenting the company's strategic outlook.

12/02/2025, 8:00 AM • GlobeNewswire

Kestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares

Kestra Medical Technologies plans to offer 5,500,000 common shares through an underwritten public offering, with potential for an additional 825,000 shares. The proceeds will support sales, marketing, research, development, and general corporate purposes.

12/01/2025, 7:16 AM • Benzinga